INmune Bio (NASDAQ:INMB) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of INmune Bio (NASDAQ:INMB) from a hold rating to a sell rating in a research report report published on Saturday morning.

Separately, Weiss Ratings upgraded INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat, INmune Bio has a consensus rating of “Moderate Buy”.

INmune Bio Stock Down 5.8%

Shares of NASDAQ INMB opened at $1.62 on Friday. The company has a market capitalization of $43.06 million, a PE ratio of -0.97 and a beta of 0.97. The stock’s 50 day moving average price is $1.55 and its 200-day moving average price is $1.46. INmune Bio has a twelve month low of $1.09 and a twelve month high of $3.24.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04.

Institutional Investors Weigh In On INmune Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in INmune Bio by 3.4% during the third quarter. Vanguard Group Inc. now owns 876,292 shares of the company’s stock valued at $1,814,000 after purchasing an additional 28,541 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of INmune Bio by 6.9% in the second quarter. Geode Capital Management LLC now owns 389,931 shares of the company’s stock worth $901,000 after purchasing an additional 25,069 shares in the last quarter. State Street Corp increased its stake in shares of INmune Bio by 22.3% in the fourth quarter. State Street Corp now owns 347,259 shares of the company’s stock worth $542,000 after purchasing an additional 63,426 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of INmune Bio by 1,042.7% in the second quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company’s stock worth $169,000 after purchasing an additional 66,700 shares in the last quarter. Finally, XTX Topco Ltd raised its position in shares of INmune Bio by 41.3% in the fourth quarter. XTX Topco Ltd now owns 68,865 shares of the company’s stock valued at $107,000 after purchasing an additional 20,121 shares during the period. 12.72% of the stock is currently owned by institutional investors.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.